89157-94-8

Basic information

• Product Name: 4-Methylumbelliferyla-L-idopyranosiduronicacidsodiumsalt
• Synonyms: a-L-Idopyranosiduronic acid,4-methyl-2-oxo-2H-1-benzopyran-7-yl, monosodium salt;4-Methyl-2-oxo-2H-1-benzopyran-7-yl alpha-L-idopyranosiduronic acid monosodium salt;4-Methylumbelliferyl alpha-L-iduronic acid sodium salt;4-Methylumbelliferyl α-L-idopyranosiduronic acid sodium salt≥ 98% (HPLC);Sodium (4-methylumbelliferyl α-L-idopyranosid)uronate;4-Methylumbelliferyl-alpha-L-iduronide Sodium Salt;a-L-Idopyranosiduronic acid,4-methyl-2-oxo-2H-1-benzopyran-7-yl, monosodium salt (9CI)
• CAS NO: 89157-94-8
• Molecular Formula: C16H15O9.Na
• Molecular Weight: 374.276
• EINECS: 1533716-785-6
• Product Categories: Carbohydrates & Derivatives;Fluorescent Labels & Indicators;Labeling and Diagnostics Reagents;substrate
• Mol File: 89157-94-8.mol

Chemical Properties

• Melting Point: 193-195°C
• Appearance: /Powder
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• CAS DataBase Reference: 4-Methylumbelliferyla-L-idopyranosiduronicacidsodiumsalt(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methylumbelliferyla-L-idopyranosiduronicacidsodiumsalt(89157-94-8)
• EPA Substance Registry System: 4-Methylumbelliferyla-L-idopyranosiduronicacidsodiumsalt(89157-94-8)

Safety Data

• Hazardous Substances Data: 89157-94-8(Hazardous Substances Data)

Usage

Uses

Used in Medical Research:
4-Methylumbelliferyla-L-idopyranosiduronicacidsodiumsalt is used as a fluorogenic substrate in the assay of α-L-Iduronidase for the detection of Hurler's syndrome. This application aids in the diagnosis and monitoring of the disease, as well as in the evaluation of potential treatments.
Used in Diagnostic Laboratories:
In diagnostic laboratories, 4-Methylumbelliferyla-L-idopyranosiduronicacidsodiumsalt serves as a valuable tool for identifying individuals with Hurler's syndrome. By measuring the activity of α-L-Iduronidase in a patient's sample, clinicians can determine if the enzyme is functioning properly, which is crucial for the proper management of the condition.
Used in Pharmaceutical Development:
4-Methylumbelliferyla-L-idopyranosiduronicacidsodiumsalt can also be employed in the development of new pharmaceuticals targeting the treatment of Hurler's syndrome. By using 4-Methylumbelliferyla-L-idopyranosiduronicacidsodiumsalt in enzyme assays, researchers can screen for potential drug candidates that may enhance α-L-Iduronidase activity or compensate for its deficiency, ultimately leading to more effective therapies for patients with this genetic disorder.